ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Heron Therapeutics Announces FDA Approval of an Indication Expansion for Zynrelef for Postoperative Pain Management
December 14, 2021Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs... -
Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients E
July 29, 2021Heron Therapeutics, Inc. today announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery have been published online by Pain and Therapy in an article entitled -
FDA Approves Zynrelef (bupivacaine and meloxicam) for the Management of Postoperative Pain
May 24, 2021HRTX today announced that FDA has approved Zynrelef extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy -
Zynrelef Anesthetic Receives FDA Approval
May 18, 2021Lifecore will manufacture the new innovative drug for treatment of postoperative pain.
Pharma Sources Insight January 2025
